Clopidogrel selectively inhibits adenosine diphosphate (ADP) from binding to its platelet P2Y12 receptor and subsequent activation of glycoprotein GPIIb/IIIa complex thus reducing platelet aggregation.
GO TO DETAILS ProductsClopidogrel selectively inhibits adenosine diphosphate (ADP) from binding to its platelet P2Y12 receptor and subsequent activation of glycoprotein GPIIb/IIIa complex thus reducing platelet aggregation.
Copyright 2025 by Quaecon Pharmaceuticals Inc.